New treatments for dementia. Myth, magic, and science

R. Ganesan; T. Standish; D. W. Molloy; P. Darzins; J. B. Orange

New treatments for dementia. Myth, magic, and science

R. Ganesan, T. Standish, D. W. Molloy, P. Darzins, J. B. Orange

Research output: Contribution to journal › Review Article › Research › peer-review

Abstract

Dementia could affect 778 000 Canadians by the year 2031. While current treatment is mainly supportive, a race to find new treatments for this dreaded disease takes varied approaches and currently accounts for 10% of drug company resources. Tacrine is the first drug licensed by the US food and Drug Administration for use in Alzheimer's disease. New treatments raise several ethical issues and involve society's attitude toward death and dying.

Original language	English
Pages (from-to)	1149-1157
Number of pages	9
Journal	Canadian Family Physician
Volume	40
Issue number	JUNE
Publication status	Published - 1 Jan 1994
Externally published	Yes

Access to Document

Link to publication in Scopus

Cite this

@article{a2f0634192404b308993772db93dc616,

title = "New treatments for dementia. Myth, magic, and science",

abstract = "Dementia could affect 778 000 Canadians by the year 2031. While current treatment is mainly supportive, a race to find new treatments for this dreaded disease takes varied approaches and currently accounts for 10% of drug company resources. Tacrine is the first drug licensed by the US food and Drug Administration for use in Alzheimer's disease. New treatments raise several ethical issues and involve society's attitude toward death and dying.",

author = "R. Ganesan and T. Standish and Molloy, {D. W.} and P. Darzins and Orange, {J. B.}",

year = "1994",

month = jan,

day = "1",

language = "English",

volume = "40",

pages = "1149--1157",

journal = "Canadian Family Physician",

issn = "0008-350X",

publisher = "College of Family Physicians of Canada",

number = "JUNE",

}

TY - JOUR

T1 - New treatments for dementia. Myth, magic, and science

AU - Ganesan, R.

AU - Standish, T.

AU - Molloy, D. W.

AU - Darzins, P.

AU - Orange, J. B.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Dementia could affect 778 000 Canadians by the year 2031. While current treatment is mainly supportive, a race to find new treatments for this dreaded disease takes varied approaches and currently accounts for 10% of drug company resources. Tacrine is the first drug licensed by the US food and Drug Administration for use in Alzheimer's disease. New treatments raise several ethical issues and involve society's attitude toward death and dying.

AB - Dementia could affect 778 000 Canadians by the year 2031. While current treatment is mainly supportive, a race to find new treatments for this dreaded disease takes varied approaches and currently accounts for 10% of drug company resources. Tacrine is the first drug licensed by the US food and Drug Administration for use in Alzheimer's disease. New treatments raise several ethical issues and involve society's attitude toward death and dying.

UR - http://www.scopus.com/inward/record.url?scp=0028308375&partnerID=8YFLogxK

M3 - Review Article

C2 - 8019192

AN - SCOPUS:0028308375

VL - 40

SP - 1149

EP - 1157

JO - Canadian Family Physician

JF - Canadian Family Physician

SN - 0008-350X

IS - JUNE

ER -